BIOMAT Database Logo BIOMAT Database Logo

Risks associated with conversion of stable patients after liver transplantation to the microemulsion formulation of cyclosporine. 1998

C E Freise, and C A Galbraith, and B J Nikolai, and N L Ascher, and J R Lake, and P G Stock, and J P Roberts
Department of Surgery, University of California, San Francisco 94143, USA.

BACKGROUND Neoral is a microemulsion formulation of cyclosporine that has a better pharmacokinetic profile than the standard formulation (Sandimmune). To prove the safety of converting stable liver transplant patients from Sandimmune to Neoral, we conducted a prospective trial involving 54 patients. METHODS The average time from transplantation to conversion was 48.5+/-21.6 months. Thirty of 54 patients (55%) required a dose reduction during the study for various reasons. Five of 30 patients had the first dose reduction because of increased levels of cyclosporine. Seven patients required more than one dose reduction. RESULTS Sixteen patients suffered serious adverse events. Six patients had a biopsy-proven rejection. Four of 6 patients had trough cyclosporine levels within 20% of baseline value immediately before developing rejection. CONCLUSIONS Converting patients from the standard formulation to the microemulsion formulation of cyclosporine seems to expose stable patients to unnecessary risks.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008107 Liver Diseases Pathological processes of the LIVER. Liver Dysfunction,Disease, Liver,Diseases, Liver,Dysfunction, Liver,Dysfunctions, Liver,Liver Disease,Liver Dysfunctions
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002626 Chemistry, Pharmaceutical Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use. Medicinal Chemistry,Chemistry, Pharmaceutic,Pharmaceutic Chemistry,Pharmaceutical Chemistry,Chemistry, Medicinal
D004655 Emulsions Colloids formed by the combination of two immiscible liquids such as oil and water. Lipid-in-water emulsions are usually liquid, like milk or lotion. Water-in-lipid emulsions tend to be creams. The formation of emulsions may be aided by amphiphatic molecules that surround one component of the system to form MICELLES. Emulsion
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

C E Freise, and C A Galbraith, and B J Nikolai, and N L Ascher, and J R Lake, and P G Stock, and J P Roberts
Conversion from tacrolimus to microemulsion formulation of cyclosporine in pediatric liver transplantation.
August 1998, Transplantation proceedings,
C E Freise, and C A Galbraith, and B J Nikolai, and N L Ascher, and J R Lake, and P G Stock, and J P Roberts
Conversion from the conventional cyclosporine formulation (Sandimmune) to a new oral microemulsion (Neoral) in stable liver transplant patients.
August 1998, Transplantation proceedings,
C E Freise, and C A Galbraith, and B J Nikolai, and N L Ascher, and J R Lake, and P G Stock, and J P Roberts
Microemulsion formulation of cyclosporine in pediatric liver transplantation.
February 1996, Transplantation,
C E Freise, and C A Galbraith, and B J Nikolai, and N L Ascher, and J R Lake, and P G Stock, and J P Roberts
Kidney function after 1:1 conversion to the cyclosporine microemulsion formulation in children with liver allografts.
June 1997, Transplantation,
C E Freise, and C A Galbraith, and B J Nikolai, and N L Ascher, and J R Lake, and P G Stock, and J P Roberts
Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients.
August 1998, Transplantation proceedings,
C E Freise, and C A Galbraith, and B J Nikolai, and N L Ascher, and J R Lake, and P G Stock, and J P Roberts
Tacrolimus to cyclosporine microemulsion formulation conversion in the pediatric liver transplant patient.
August 1998, Transplantation proceedings,
C E Freise, and C A Galbraith, and B J Nikolai, and N L Ascher, and J R Lake, and P G Stock, and J P Roberts
Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year.
May 1996, Clinical nephrology,
C E Freise, and C A Galbraith, and B J Nikolai, and N L Ascher, and J R Lake, and P G Stock, and J P Roberts
Conversion from regular cyclosporine to microemulsion cyclosporine following heart transplantation.
December 1996, Transplantation proceedings,
C E Freise, and C A Galbraith, and B J Nikolai, and N L Ascher, and J R Lake, and P G Stock, and J P Roberts
Conversion and pharmacokinetic studies of a microemulsion formulation of cyclosporine in pediatric liver transplant patients.
October 1996, Transplantation,
C E Freise, and C A Galbraith, and B J Nikolai, and N L Ascher, and J R Lake, and P G Stock, and J P Roberts
Conversion of patients to cyclosporine E microemulsion.
May 1998, Transplantation proceedings,
Copied contents to your clipboard!